Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (141-150 of 531) with videos related to

Pageof 54
Sort By:
Pharmacotherapy|November 23, 2001
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and reviewA L Kwa, V H Tam, M J Rybak
International Journal of Antimicrobial Agents|July 13, 2013
Daptomycin: the role of high-dose and combination therapy for Gram-positive infectionsIan M Gould, José M Miró, Michael J Rybak
Antimicrobial Agents and Chemotherapy|June 1, 1991
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycinE M Bailey, M J Rybak, G W Kaatz
Diagnostic Microbiology and Infectious Disease|February 10, 2006
Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteriaRobert J Kerns, Michael J Rybak, Chrissy M Cheung
Clinical Pharmacokinetics|January 1, 1992
Ofloxacin clinical pharmacokineticsK C Lamp, E M Bailey, M J Rybak
Expert Opinion on Pharmacotherapy|July 24, 2013
Current and prospective treatments for multidrug-resistant gram-positive infectionsJeffrey M Rybak, Katie E Barber, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|July 7, 2000
Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection modelH H Houlihan, D P Stokes, M J Rybak
Antimicrobial Agents and Chemotherapy|June 4, 2008
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureusSteven N Leonard, Chrissy M Cheung, Michael J Rybak
Pharmacotherapy|October 24, 2007
Case study and panel discussionDennis G Maki, Steven C Ebert, Michael J Rybak
International Journal of Antimicrobial Agents|August 4, 2004
In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic modelGeorge P Allen, Glenn W Kaatz, Michael J Rybak
Pageof 54

Showing results (141-150 of 531) with videos related to

Sort By:
Pageof 54
Pharmacotherapy|November 23, 2001
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and reviewA L Kwa, V H Tam, M J Rybak
International Journal of Antimicrobial Agents|July 13, 2013
Daptomycin: the role of high-dose and combination therapy for Gram-positive infectionsIan M Gould, José M Miró, Michael J Rybak
Antimicrobial Agents and Chemotherapy|June 1, 1991
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycinE M Bailey, M J Rybak, G W Kaatz
Diagnostic Microbiology and Infectious Disease|February 10, 2006
Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteriaRobert J Kerns, Michael J Rybak, Chrissy M Cheung
Clinical Pharmacokinetics|January 1, 1992
Ofloxacin clinical pharmacokineticsK C Lamp, E M Bailey, M J Rybak
Expert Opinion on Pharmacotherapy|July 24, 2013
Current and prospective treatments for multidrug-resistant gram-positive infectionsJeffrey M Rybak, Katie E Barber, Michael J Rybak
The Journal of Antimicrobial Chemotherapy|July 7, 2000
Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection modelH H Houlihan, D P Stokes, M J Rybak
Antimicrobial Agents and Chemotherapy|June 4, 2008
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureusSteven N Leonard, Chrissy M Cheung, Michael J Rybak
Pharmacotherapy|October 24, 2007
Case study and panel discussionDennis G Maki, Steven C Ebert, Michael J Rybak
International Journal of Antimicrobial Agents|August 4, 2004
In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic modelGeorge P Allen, Glenn W Kaatz, Michael J Rybak
Pageof 54